Skip to main content
. 2016 Nov 4;7(50):83319–83329. doi: 10.18632/oncotarget.13066

Figure 2. Six-gene model predicts overall survival (OS) in diffuse large B-cell lymphoma (DLBCL) patients treated with Rituximab, cyclophosphamide, doxorubicin (hydroxydaunomycin), vincristine (Oncovin ®), prednisolone (a steroid) (R-CHOP) and CHOP chemotherapy within an international multi-centre setting.

Figure 2

Kaplan-Meier curves of 162 patients. A. show significant extended OS of low risk patients as defined by 6-gene predictor score (p<0.01; patient numbers Low n=81, High n=81); B. show no significant EFS of low risk patients as defined by the 6-gene predictor score (p=0.18; patient numbers Low n=81, High n=81).